Cognito Therapeutics and Providence Health Plan Initiate Phase 3 Study to Evaluate Disease-Modifying Treatments in Mild Cognitive Impairment

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough noninvasive therapy for patients with mild cognitive impairment (MCI).

Phase 3 real-world evidence study will evaluate the safety, efficacy, and cost-effectiveness of Cognito’s therapeutic platform in patients with MCI treated within Providence Health’s network of nationally recognized neurology specialists Plan. This first-of-its-kind registrational study is expected to begin in the second quarter of 2022, alongside Cognito’s pivotal Phase 3 study in patients with mild to moderate Alzheimer’s disease (AD).

“New technologies, such as Cognito’s disease-modifying therapy, are key to improving outcomes for patients with MCI,” said Dr. Nancy Isenberg, Medical Director of the Center for Healthy Aging at the Swedish Neuroscience Institute. . “Currently, no drugs have been approved for the treatment of MCI, and patients need new options that are safe, effective and affordable.”

“We look forward to collaborating with Providence Health Plan on our Phase 3 programs evaluating our disease-modifying intervention across the spectrum of patients from MCI to mild to moderate Alzheimer’s disease,” said Brent Vaughan, CEO of Cognito Therapeutics. “Our proprietary therapeutic platform has the potential to create an entirely new approach to clinically meaningful improvements in patients across a wide range of neurodegenerative and neuropsychiatric conditions.”

“Given our focus on MCI, Alzheimer’s disease and other life-threatening neurodegenerative diseases, we believe it is imperative to collaborate and partner with leading payer and provider organizations such as Providence Health Plan to develop concrete, economic and clinical evidence of health in a diversity of populations,” said Dr. Tom Megerian, Chief Medical Officer, Cognito Therapeutics. partner patients, to have the evidence and the confidence to deploy and use our therapeutic platform with the millions of patients living with these devastating diseases.”

“There is a need for safe and cost-effective treatments for MCI and AD, to ensure that new treatments are rapidly adopted and that access is provided to all patients who could benefit from them,” said Dr. Robert Gluckman, CMO of Providence Health Plan. . “About 12-18% of people aged 60 or older live with MCI, and new therapies that can be deployed early in treatment to delay or halt disease progression are desperately needed.”

This recently initiated study with Providence Health Plan is part of a larger multi-study Phase 3 program evaluating Cognito’s disease-modifying optogenetic-based therapy in patients with MCI and mild-to-moderate AD.

About Cognito Therapeutics

Cognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance. The company has performed several clinical studies demonstrating that its experimental therapeutic platform has the potential to safely slow or arrest cognitive decline and brain volume loss in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and plans to begin pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research conducted by the scientific co-founders, professors Li-Huei Tsai and Ed Boyden at MIT. Cognito Therapeutics is based in Cambridge, MA. For more information, please visit www.cognitotx.com. Follow us on Twitter at @cognitotx.

About Providence Health Plan

Providence Health Plan (PHP) is part of a 160-year-old nonprofit integrated health care system that has set the standard of health and wellness for the communities we serve. PHP provides high-quality, affordable coverage to members through small and large group plans, self-insured plan sponsors, Medicare and Medicaid beneficiaries, and individuals and families. We offer a range of benefits including comprehensive health care, 24/7 access to telehealth visits, behavioral health resources, and personalized health coaching.

Comments are closed.